PLAUR and neoplasm: Accordingly, several studies have reported that uPAR-targeted nanoplatforms modified by the uPA peptide possessed great potential in enhancing tumor targeting, improving delivery efficiency, reducing drug toxicity, and in multimodal synergistic antitumor applications [41–44].